SecBot SecBot

SER

Serina Therapeutics, Inc.
NYSE· Pharmaceutical Preparations· Inc. AL· CIK 0001708599 Biotech & Drug Discovery
$1.71 +0.06 (+3.64%)
Oct 26 4:00 PM ET · prev $1.65
Market cap
$44.7M
Nano cap
Consensus
Buy
83% Buy or better · 6 analysts
Median target
$9.50
+456% · range $8.00–11.00
Next earnings
Nov 18
in 23 days
1 year
−66.3%
from $5.07 · Oct 27
30 days
−14.9%
from $2.01
52-week range
$1.28–5.09
−66% from high · low Mar 18
Avg volume 20D
33.2K
Oct 12 spike 132.2K
Short interest
56.6K
≈0.2% of shares · −52.6%
Days to cover
1.0
at average volume
Insider net
−$57.8K
4 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Serina Therapeutics announced that the Independent Safety Monitoring Committee completed its blinded review…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    4 insiders bought $77.9K at an average $1.78. 1 insider sold $135.7K.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    5 of 6 rate it Buy or better. Every target is above the price.

  • Short sellersCOVERING

    Short interest −52.6% to 56.6K shares. 1.0 days to cover, ≈0.2% of shares.

  • TrendDOWNTREND

    23% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCTRIM15,444$30.0K
BlackRock, Inc.NEAR_EXIT2,378$4.6K
OSAIC HOLDINGS, INC.DOUBLED2,002$3.9K
UBS Group AGDOUBLED1,347$2.6K
MORGAN STANLEYADD14$28.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED64,973$126.0K
BlackRock, Inc.DOUBLED58,264$113.0K
OSAIC HOLDINGS, INC.DOUBLED1,001$1.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

6 analysts
Buy 83% rate it Buy or better
Strong Buy2Buy3Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +456%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 26, 2026🔒 Fresh data, subscribers only
REITERATE
REITERATE
Sep 10, 2026BTIG
REITERATE
REITERATEBuy
Jul 1, 2026BTIG
INITIATE
INITIATEBuy

Insider ledger

Form 4
$77.9K
bought · 4 insiders
$135.7K
sold · 1 insider
−3.7%
vs their $1.78 cost
DateInsiderTypeValue
Jul 22, 2026
Simon Farrell
Director
AWARD30,500 sh
Jul 7, 2026
Brannan Stephen K.
Director
BUY$2.0K
Jun 17, 2026
Marshall Richard Peter
Director
AWARD15,250 sh
Jun 17, 2026
WILSON KAREN J
Director
AWARD15,250 sh
Jun 17, 2026
Brannan Stephen K.
Director
AWARD15,250 sh
Jun 17, 2026
Bailey Gregory
Director
CONVERT$4.0M
Jun 17, 2026
Bailey Gregory
Director
AWARD15,250 sh
Jun 17, 2026
Bailey Gregory
Director
AWARD3,333,333 sh

Earnings setup

Estimates
Nov 18
reports in 23 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
56,600
shares short
-52.6%
vs prior settlement
1.0
days to cover
≈0.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Other
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026
Sep 9, 2026 SEC
Serina Therapeutics announced that the Independent Safety Monitoring Committee completed its blinded review of Cohort…
8-K — Impact 6/10
Jul 23, 2026 SEC
Serina Therapeutics completed enrollment in Cohort 1 of its Phase 1b registrational trial for SER-252 (Parkinson's…
PRESS-RELEASE — Impact 5/10
Jul 22, 2026 SEC
Serina Therapeutics appointed Farrell Simon, Pharm.D., to its Board of Directors, effective July 22, 2026. Dr. Simon…
8-K — Impact 2/10
Jul 22, 2026 Insider
Simon Farrell was granted 30,500 shares
Director
Jul 7, 2026 Insider
Brannan Stephen K. bought 1,000 shares
Director @ $2.03 ($2.0K)
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — TRIM
15,444 shares ($30.0K)
Jun 30, 2026 Inst.
BlackRock, Inc. — NEAR_EXIT
2,378 shares ($4.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
SER Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Sep 23, 2026
Press release
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026
Sep 9, 2026
Press release
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data –
Aug 7, 2026
Earnings date
SER Q2 2026 Earnings Scheduled — 2026-08-07
Aug 3, 2026
Earnings date
SER Q2 2026 Earnings Scheduled — 2026-08-03
Jul 24, 2026
Press release
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage…

SecBot reports

8 filings · 1 press release · 1 bullish · 3 bearish · 2 mixed · 2 neutral
All SER filing & press-release reports (9)